A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 May 2019
Price : $35 *
At a glance
- Drugs MK 4334 (Primary) ; Donepezil
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 02 May 2019 Planned End Date changed from 28 Oct 2019 to 28 Feb 2020.
- 02 May 2019 Planned primary completion date changed from 28 Oct 2019 to 28 Feb 2020.
- 02 May 2019 Planned initiation date changed from 28 May 2019 to 27 Sep 2019.